Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2005-10-25 Capital/Financing Update
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Fresenius AG:Fresenius resolves on capital increase and defines terms
Capital/Financing Update Classification · 99% confidence The document is an 'Ad hoc announcement' dated October 25, 2005, detailing that Fresenius AG has resolved to increase its subscribed share capital by issuing new ordinary and preference shares. It specifies subscription ratios, prices, expected proceeds (EUR 840 million), and timelines for trading rights and final pricing. This content directly relates to fundraising, financing activities, and changes to the capital structure. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an earnings release, an annual report, or a simple announcement of a report publication.
2005-10-25 English
Fresenius AG: Fresenius continues profitable growth
Earnings Release Classification · 100% confidence The document is an 'Ad hoc announcement' dated October 14, 2005, transmitted by DGAP. It details significant corporate actions: the acquisition of HELIOS Kliniken GmbH, the acquisition of Clinico GmbH, committed financing plans (capital increase and bond issuance), and preliminary excellent financial results for the first 9 months of 2005, leading to a raised earnings guidance. This content—announcing major strategic moves, financing, and preliminary results—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it provides key financial highlights and strategic updates immediately, it fits the 'Earnings Release' definition best, even though it also covers M&A and financing. It is not a full 10-K, IR, or a transcript. Given the focus on preliminary results and raised guidance, ER is the most appropriate fit among the specific financial reporting codes. 9M 2005
2005-10-14 English
Akquisition HELIOS und Clinico, 1.-3. Quartal 2005 (vorläufig)
Investor Presentation Classification · 100% confidence The document is titled 'Analyst Meeting, October 14, 2005' and contains an agenda, detailed slides, strategic rationale, financial impact analysis related to acquisitions (HELIOS and Clinico), and performance highlights for Q1-3/2005. This structure—a presentation format delivered to analysts covering strategy, M&A, and recent performance—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it a short announcement (RPA/RNS).
2005-10-14 English
Fresenius AG: Voting of Fresenius AG
AGM Information Classification · 99% confidence The document is an 'Ad hoc announcement' dated August 15, 2005, concerning the voting intentions of Fresenius AG regarding a countermotion submitted for an Extraordinary General Meeting (EGM) of Fresenius Medical Care AG scheduled for August 30, 2005. The content specifically discusses shareholder votes, countermotions, and the conversion of preference shares. This directly relates to the voting process and results of a general meeting, even though it is an announcement of intent rather than final results. The most fitting category is 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it pertains to the mechanics and outcomes/intentions surrounding shareholder votes at a general meeting. It is not a full report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about shareholder voting.
2005-08-15 English
Q2 Report 2005
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report 1st Half and 2nd Quarter 2005' and contains comprehensive financial statements, management discussion and analysis (MD&A), segment reporting, and notes for the specified period. It is a full financial report for a period shorter than a fiscal year, not an announcement or a summary, fitting the definition of an Interim/Quarterly Report. H2 2005
2005-08-11 English
Fresenius AG: Excellent financial results; full-year earnings outlook raised
Earnings Release Classification · 100% confidence The document is an 'Ad hoc announcement' dated August 4, 2005, detailing the 'First half of 2005' financial results (Sales, EBIT, Net income, EPS) and subsequently raising the 'full-year earnings outlook'. This structure—a brief, immediate release of key financial figures for a recent period (H1 2005) that is not the full annual report—is characteristic of an Earnings Release (ER). It provides the highlights and outlook adjustment, rather than the comprehensive details found in an Interim Report (IR) or Annual Report (10-K). The document length is short (1962 chars), supporting the classification as a summary release rather than a full report. H1 2005
2005-08-04 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.